ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Senate Emphasizes Balance In NCI’s Research Programs

September 24, 1993

NCI T BE More Flexible In Funding RFAs Above Paylines

June 23, 1989

Researchers Uncover Tumors Sensitive to Chemotherapy

January 25, 2013

NEJM Papers, Interview With NCI’s Doroshow, Provide Justification For Regulatory Action on ESAs.

June 15, 2007

‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’

September 20, 1991

NCI Study Tests Method For Biomarker Validation

July 24, 2009